Athersys (NASDAQ:ATHX) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of Athersys (NASDAQ:ATHX) in a research report report published on Tuesday morning. The firm issued a hold rating on the biopharmaceutical company’s stock.

Athersys Price Performance

The company has a market capitalization of $833,000.00, a PE ratio of -0.01 and a beta of -0.90. Athersys has a one year low of $0.01 and a one year high of $1.99.

Athersys Company Profile

Athersys, Inc, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.